media center

March 18, 2021 Augustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases

December 16, 2019 VIB and KU Leuven announce new spin-off Augustine Therapeutics to fight neuromuscular diseases

March 19,  2021 Augustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board

March 23, 2021 Augustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases

2021 all rights reserved.